A-Alpha Bio's AlphaSeq is a synthetic biotechnology that measures interactions between biologics libraries and multiple targets in a single experimental step, reducing time and cost while improving success rates. The team consists of synthetic biologists, structural biologists, and next-generation sequencing experts who aim to remove the industry-wide bottleneck in drug development. AlphaSeq is a revolutionary cell-based platform technology that will change the way protein interactions are measured, and the company seeks industry partnerships to evaluate its use for various drug development applications. Founded in 2017 as a spinout from the University of Washington, A-Alpha Bio aims to accelerate target discovery, library screening, and preclinical drug characterization.